Chimerix reported Q2 2024 financial results and provided operational updates. The company's Phase 3 ACTION study for dordaviprone in H3 K27M-mutant diffuse glioma is on track, with first interim overall survival data expected in Q3 2025. Chimerix also filed for Provisional Determination with Australia's TGA for dordaviprone.ONC206, a second-generation ClpP agonist, has shown promising Phase 1 data with dose-proportional exposure and no dose-limiting toxicity to date. The company expects to complete enrollment in ONC206 dose escalation trials by end of 2024. Chimerix reported a net loss of $20.7 million for Q2 2024, compared to $18.6 million in Q2 2023.The company's balance sheet as of June 30, 2024, included $171.5 million in available capital, with no outstanding debt. Chimerix continues to focus on developing medicines for patients facing deadly diseases, with a particular emphasis on central nervous system tumors.

Chimerix reported Q2 2024 financial results and provided operational updates. The company's Phase 3 ACTION study for dordaviprone in H3 K27M-mutant diffuse glioma is on track, with first interim overall survival data expected in Q3 2025. Chimerix also filed for Provisional Determination with Australia's TGA for dordaviprone.ONC206, a second-generation ClpP agonist, has shown promising Phase 1 data with dose-proportional exposure and no dose-limiting toxicity to date. The company expects to complete enrollment in ONC206 dose escalation trials by end of 2024. Chimerix reported a net loss of $20.7 million for Q2 2024, compared to $18.6 million in Q2 2023.The company's balance sheet as of June 30, 2024, included $171.5 million in available capital, with no outstanding debt. Chimerix continues to focus on developing medicines for patients facing deadly diseases, with a particular emphasis on central nervous system tumors.